亘喜生物宣布FasTCAR-T GC012F早线治疗多发性骨髓瘤的1期新药临床试验（IND）申请获美国FDA批准

January 29, 2024

https://www.globenewswire.com/news-release/2024/01/29/2818739/0/zh-hans/%E4%BA%98%E5%96%9C%E7%94%9F%E7%89%A9%E5%AE%A3%E5%B8%83FasTCAR-T-GC012F%E6%97%A9%E7%BA%BF%E6%B2%BB%E7%96%97%E5%A4%9A%E5%8F%91%E6%80%A7%E9%AA%A8%E9%AB%93%E7%98%A4%E7%9A%841%E6%9C%9F%E6%96%B0%E8%8D%AF%E4%B8%B4%E5%BA%8A%E8%AF%95%E9%AA%8C-IND-%E7%94%B3%E8%AF%B7%E8%8E%B7%E7%BE%8E%E5%9B%BDFDA%E6%89%B9%E5%87%86.html

中国江苏苏州、上海和美国加利福尼亚州圣迭戈, Jan. 29, 2024 (GLOBE NEWSWIRE) — 亘喜生物科技集团（纳斯达克股票代码：GRCL；简称“亘喜生物” 或“公司”） 是一家面向全球、处于临床阶段的生物制药企业，致力于开发创新、高效的细胞疗法以治疗癌症及自身免疫性疾病。今日，公司宣布美国食品药品监督管理局（FDA）正式批准了FasTCAR-T GC012F疗法的又一项新药临床试验（IND）申请，准许公司在美国启动GC012F早线治疗多发性骨髓瘤(ELMM)1期临床试验。

Read more at globenewswire.com

Related news for (GRCL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.